Abstract
Background and ImportanceThe anti-PCSK9 monoclonal antibodies alirocumab and evolocumab were authorised in 2015 for the treatment of primary hypercholesterolaemia (heterozygous HeFH or non-family noFH) or mixed dyslipidaemia (MD). They have...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have